THE WNT SIGNALING PATHWAY: AGING GRACEFULLY AS A PROTECTIONIST?

Kenneth Maiese1,2, Faqi Li1, Zhao Zhong Chong1, and Shang Yen Chen1
1Division of Cellular and Molecular Cerebral Ischemia, Wayne State University School of Medicine, Detroit, Michigan 48201
2Departments of Neurology and Anatomy & Cell Biology, Barbara Ann Karmanos Cancer Institute, Center for Molecular Medicine and Genetics, Institute of Environmental Health Sciences, Detroit, Michigan 48201

Abstract

No longer considered to be exclusive to cellular developmental pathways, the Wnt family of secreted cysteine-rich glycosylated proteins has emerged as versatile targets for a variety of conditions that involve cardiovascular disease, aging, cancer, diabetes, neurodegeneration, and inflammation. In particular, modulation of Wnt signaling may fill a critical void for the treatment of disorders that impact upon both cellular survival and cellular longevity. Yet, in some scenarios, Wnt signaling can become the catalyst for disease development or promote cell senescence that can compromise clinical utility. This double edge sword in regards to the role of Wnt and its signaling pathways highlights the critical need to further elucidate the cellular mechanisms governed by Wnt in conjunction with the development of robust pharmacological ligands that may open new avenues for disease treatment. Here we discuss the influence of the Wnt pathway during cell survival, metabolism, and aging in order for one to gain a greater insight for the novel role of Wnt signaling as well as exemplify its unique cellular pathways that influence both normal physiology and disease.

Keywords

Alzheimer’s disease; apoptosis; cardiac; diabetes; stem cells; Wnt

1. Introduction

1.1 The Discovery of the Wnt Pathway

Wnt proteins, derived from the Drosophila Wingless (Wg) and the mouse Int-1 genes, have been shown to play a role in both cell development and cell demise (Chong et al., 2007a; Chong et al., 2007c; Li et al., 2006c; Speese & Budnik, 2007). Wnt proteins are secreted cysteine-rich glycosylated proteins that play a role in a variety of cellular functions that involve embryonic cell proliferation, differentiation, survival, and death (Li et al., 2006c; Patapoutian & Reichardt, 2000; Wodarz & Nusse, 1998). More than eighty target genes of Wnt signaling pathways have been demonstrated in human, mouse, Drosophila, Xenopus, and zebrafish. This representation encompasses several cellular populations, such as neurons, cardiomyocytes, endothelial cells,
cancer cells, and pre-adipocytes (Chong & Maiese, 2004; Li et al., 2005). Furthermore, at least nineteen of twenty-four Wnt genes that express Wnt proteins have been identified in the human.

The Wnt pathway was initially identified as a proto-oncogene in mammary tumors that was activated by integration of the mouse mammary virus (Nusse & Varmus, 1982). Since then, components of the Wnt signaling pathway have begin linked to tumorigenesis such as with adenomatous polyposis (Munemitsu et al., 1995), colon carcinoma (Morin et al., 1997), medulloblastoma (Dahmen et al., 2001; Sauvageot et al., 2007), tuberous sclerosis (Jozwiak & Wlodarski, 2006), and lung cancer (Xu et al., 2007). Subsequent work has demonstrated the importance of Wnt-Frizzled (FZD) transduction pathway in controlling the pattern of the body axis as well as the development and maturation of the central nervous system (Augustine et al., 1993; Ikeya et al., 1997), cardiovascular system (Marvin et al., 2001; Naito et al., 2006; Palpant et al., 2007; Singh et al., 2007), and the limbs (Kengaku et al., 1997) (Table 1).

During embryological development, alternations of the Wnt-FZD pathway can lead to abnormal morphogenesis in animal models (Ikeya et al., 1997; Liu et al., 1999; Stark et al., 1994) and congenital defects in humans (Jordan et al., 2001; Niemann et al., 2004; Rodova et al., 2002). In mature tissues, the Wnt-FZD pathway is involved in the self-renewal of pluripotent embryonic stem cells (Bakre et al., 2007), bone formation (Canalis et al., 2007), and may be responsible for the maintenance of many normal tissues (He et al., 2004; Reya et al., 2003; Ross et al., 2000; Willert et al., 2003) as well as cellular senescence (Liu et al., 2007). Other studies have revealed that dysfunction of the Wnt-FZD pathway can lead to neurodegenerative disorders, such as Alzheimer’s disease (Balaraman et al., 2006; Chong et al., 2007a; Marambaud et al., 2002; Morin et al., 2004; Soriano et al., 2001) and heart failure (Barandon et al., 2003; Barandon et al., 2005; Li et al., 2006c; van de Schans et al., 2007).

1.2 Functional Classes and Receptors of Wnt Proteins

The molecular structural characteristics that all Wnt proteins share with varying degrees of sequence identity involve the 39–46 kDa lipid-modified secreted glycoproteins containing 350–400 amino acids with a highly conserved pattern of 23–24 cysteine residues and several asparagines-linked glycosylation sites (Li et al., 2005, 2006c). Some Wnt proteins also have an additional domain, such as the Drosophila Wg, that contains an 85-amino acid domain near the center of the protein (Nusse & Varmus, 1992). Wnt proteins are generally divided into functional classes based on their ability to induce a secondary body axis in Xenopus embryos and to activate certain signaling cascades that consist of the Wnt1 class and the Wnt5a class. These involve intracellular signaling pathways that are critical for Wnt signal transduction. However, it should be stated that the lines between these pathways are sometimes blurred and not distinct, especially with the reliance upon common pathways that can involve calcium signaling and Dishevelled (DVL), a cytoplasmic multifunctional phosphoprotein (Axelrod et al., 1998; Boutros et al., 1998). The mammalian DVL protein family contains DVL-1, DVL-2, and DVL-3. DVL family members have three conserved domains that include an N-terminal DIX domain named for DVL and Axin, a central PDZ domain termed for Postsynaptic density-95, Discs-large and Zonula occludens-1, and a C-terminal DEP that is named for DVL, Egl-10 and Pleckstrin. DVL is a key transducer of Wnt signaling that acts at the plasma membrane or in the cytoplasm in all three Wnt-FZD signaling pathways. Yet, DVL also acts within the nucleus, since nuclear localization of DVL can be vital for functioning in the Wnt-FZD signaling pathway (Itoh et al., 2005).

One of the Wnt pathways controls target gene transcription through β-catenin, generally referred to as the canonical pathway that involves Wnt1, Wnt3a, and Wnt8 (Figure 1). The members of the Wnt1 class are inducers of a secondary body axis in Xenopus and include Wnt1, Wnt2, Wnt3, Wnt3a, Wnt8, and Wnt8a. Wnt proteins of this class facilitate activation of the
FZD transmembrane receptor and the co-receptor lipoprotein related protein 5 and 6 (LRP-5/6). Ultimately, this leads to the activation of the Wnt/β-catenin pathway and DVL.

Other Wnt pathways pertain to intracellular calcium (Ca\(^{2+}\)) release (Figure 1). These involve the non-canonical or Wnt/Ca\(^{2+}\) pathway consisting primarily of Wnt-4, Wnt-5a, and Wnt-11 that functions through non-β-catenin-dependent pathways and also include the planar cell polarity (PCP) pathway (Patapoutian & Reichardt, 2000) and the Wnt-Ca\(^{2+}\)-dependent pathways (Patapoutian & Reichardt, 2000; Slusarski et al., 1997). The Wnt5α class cannot induce secondary axis formation in *Xenopus* and includes the Wnt proteins of Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, and Wnt11. Wnt proteins in the PCP pathway bind the FZD transmembrane receptor and employ DVL to activate effector pathways through Rho/Rac small GTPase and Jun N-terminal kinase (JNK) (Seifert & Mlodzik, 2007). In the Wnt-Ca\(^{2+}\)-dependent pathways, calcium dependent kinases are activated through G-protein signaling that leads to elevations in intracellular Ca\(^{2+}\) either through cGMP or phospholipase activation (Ma & Wang, 2006; Schulte & Bryja, 2007; Slusarski et al., 1997).

The receptors of Wnt proteins consist of at least ten mammalian isoforms of the FZD family. The FZD proteins are named after the first member of the *Drosophila* tissue polarity gene *Frizzled* (Adler et al., 1990; Vinson et al., 1989). Members of the FZD protein family are listed as a distinct family of G-protein-coupled receptors (Foord et al., 2005). The FZD proteins have a N-terminal signal peptide, an extracellular domain that contains a 120-amino acids, a cysteine-rich domain followed by a hydrophilic linker region that shows little sequence similarity among family members, a highly conserved seven-transmembrane domain separated by short extracellular and cytoplasmic loops, and a cytoplasmic domain of variable size and little sequence homology among family members (Adler et al., 1990; Vinson et al., 1989; Wodarz & Nusse, 1998). Some Wnt proteins, such as Wnt8, can directly bind with the full-length FZD receptor protein. A single Wnt protein also can bind to a combination of FZD receptor proteins, including homologous members from a different species (Hsieh et al., 1999b). Interestingly, FZD proteins can bind proteins from other protein families, such as R-spondin and Norrin, and the FZD cysteine-rich domain also exists in several other proteins that include the soluble secreted FZD-related proteins (sFRPs) (Mayr et al., 1997; Melkonyan et al., 1997), some receptors of tyrosine kinases (Jennings et al., 1993; Wilson et al., 1993), carboxypeptidase Z (Song & Fricker, 1997), the membrane-bound serine protease Corin (Yan et al., 1999), and an isoform of collagen (Rehn & Pihlajaniemi, 1995). These proteins appear to function as important regulators during Wnt-FZD signaling. For example, the sFRPs have been found to function as antagonists of the Wnt pathway (Hsieh et al., 1999a; Mayr et al., 1997; Melkonyan et al., 1997).

In addition to the FZD protein receptors, other obligate co-receptors also are necessary for canonical Wnt-FZD signaling pathway. A transmembrane protein termed LRP-5/6 from the low-density-lipoprotein receptor family is required (Pinson et al., 2000; Tamai et al., 2000; Wehrli et al., 2000). In the canonical Wnt-FZD pathway, Wnt binds to both the FZD receptor and the co-receptor low-density lipoprotein receptor-related protein 5/6 (LRP-5/6) (Wehrli et al., 2000) resulting in the inhibition of the downstream component glycogen synthase kinase-3β (GSK-3β). Wnt signaling also can be transmitted through the binding of extracellular domain of LRP-5/6 to Axin, a key component in the GSK-3β complex, indicating that the LRP-5/6 receptor is an important part of the Wnt-FZD signaling pathway (Mao et al., 2001; Tolwinski et al., 2003).

Ryk also represents another co-receptor that belongs to one of divergent members of the receptor tyrosine kinase family. Ryk not only can form a complex with FZD proteins such as the co-receptor LRP-5/6 resulting in activation of the canonical Wnt-FZD signaling pathway, but also can regulate the non-canonical Wnt-FZD signaling pathway through FZD independent
pathways (Bejsovec, 2005; Lu et al., 2004). The molecular structure of all Ryk genes is characterized by an extracellular domain with homology to Wnt inhibitory factor-1 (WIF1), a single transmembrane-spanning sequence to which Wnt proteins bind (Schneider et al., 1999). In addition, a conserved intracellular PDZ-binding motif exists which links Ryk to downstream molecules of Wnt-FZD signaling pathway, such as DVL (Bejsovec, 2005; Lu et al., 2004). Wnt proteins can bind to the extracellular domain of the Ryk receptor through the intracellular PDZ-binding domain in the Ryk receptor to regulate multiple cellular functions through either the canonical or the non-canonical Wnt-FZD signaling pathway. For example, mammalian Ryk can function as a co-receptor with FZD to bind to Wnt1 and Wnt3a through its WIF domain and interact with DVL via its PDZ domain resulting in the stimulation of neurite outgrowth (Lu et al., 2004).

1.3 The Canonical and Non-Canonical Wnt Pathways

The canonical Wnt signaling pathway is referred to as the Wnt/β-catenin pathway since it can regulate β-catenin protein levels to control the activation of Wnt-responsive target genes (Figure 1). All Wnt signaling pathways are initiated by interaction of Wnt proteins with FZD receptors, but in this pathway, the Wnt signaling pathway will only be activated if the binding of the Wnt protein to the FZD receptor takes place in the presence of the co-receptor LRP-5/6 resulting in the formation of a Wnt-FZD-LRP-5/6 tri-molecular complex (Mao et al., 2001; Pinson et al., 2000; Wehrli et al., 2000). Once Wnt protein binds to the FZD receptor and the co-receptor LRP-5/6, this is followed by recruitment of DVL. DVL is phosphorylated by casein kinase Iε to form a complex with Frat1 and inhibit GSK-3β activity (Kishida et al., 2001; Lee et al., 1999; Papkoff & Aikawa, 1998).

The formation of the Wnt-FZD-LRP-5/6 complex also promotes the LRP-5/6-mediated degradation of Axin (Mao et al., 2001). The inhibition of GSK-3β activity by Wnt with the degradation of Axin blocks the formation of the protein complex consisting of GSK-3β, Axin, and adenomatous polyposis coli (APC) tumor suppressor protein. If the formation of the protein complex of GSK-3β, Axin and APC tumor suppressor protein does not occur, accumulation of free β-catenin results for translocation to the nucleus (Ikeda et al., 1998). Once positioned in the nucleus, the free β-catenin acts as a transcription factor and activates Tcf and Lef by forming nuclear complexes with Frat1 and inhibit GSK-3β activity (Kishida et al., 2001; Lee et al., 1999; Papkoff & Aikawa, 1998).

The canonical Wnt signaling pathway also is activated by several other cellular mechanisms. The shifting of proteins from the cadherin-bound pool to the cytoplasmic pool can increase the amount of available free β-catenin for the activation of target genes. Several receptor tyrosine kinases can phosphorylate tyrosine residues of the β-catenin and cadherin-catenin complex to allow β-catenin to become dissociated from the complex and increase the amount of β-catenin in the cytoplasm for subsequent translocation to the nucleus. Furthermore, surface receptors, such as epidermal growth factor receptor, c-RON, cErbB2, and erythropoietin receptor (EPOR) can then stimulate the canonical Wnt signaling pathway (Bonvini et al., 2001; Danilkovitch-Miagkova et al., 2001; Graham & Asthagiri, 2004; Li et al., 2006b). In addition, both insulin-like growth factor and erythropoietin (EPO) lead to β-catenin stabilization (Li et al., 2006b; Playford et al., 2000). The canonical Wnt signaling pathway also regulates cyclin D1 through the inhibition of GSK-3β and cAMP-responsive element-binding protein (CREB) pathway (D’Amico et al., 2000) as well as protein kinase A and CREB (Chen et al., 2005).
The non-canonical or atypical Wnt signaling pathway has two intracellular signaling cascades that consist of the Wnt/Ca\(^{2+}\) pathway and the Wnt/PCP pathway (Figure 1). In the Wnt/Ca\(^{2+}\) pathway, Wnt protein binds to FZD receptors on the cell surface resulting in several cellular processes that involve stimulation of heterotrimeric G proteins, increased intracellular Ca\(^{2+}\) release, decreased cyclic guanosine monophosphate (cGMP) levels, and activation of the two kinases Ca\(^{2+}\)-calmodulin-dependent protein kinase II (CamKII) or calcineurin (CaCN) and protein kinase C (PKC). Activation of these pathways can stimulate nuclear factor (NF)-AT and other transcription factors (Li et al., 2006c; Wang & Malbon, 2003). Thus, the Wnt/Ca\(^{2+}\) pathway is most likely a G-protein dependent signaling pathway (Chong & Maiese, 2004; Maiese et al., 2005a; Wang & Malbon, 2004). In the Wnt/PCP pathway, Wnt proteins bind to FZD receptors on the cell surface followed by activating Rho/Rac small GTPase (Habas et al., 2003) and JNK (Moriguchi et al., 1999) to assist in the subsequent regulation of cytoskeletal organization and gene expression.

Interestingly, several of the downstream proteins identified in the Wnt-FZD signaling pathway can independently function with proteins from other cellular systems. For example, DVL is able to directly regulate JNK activity (Li et al., 1999) and GSK-3\(\beta\) activity (Boutros et al., 1998). Free \(\beta\)-catenin also can form a complex with \(\alpha\)-catenin and members of cadherins family to function as a structural adaptor protein linking cadherins to the actin cytoskeleton in cell-cell adhesion processes. Association with cadherins can effectively sequester \(\beta\)-catenin from the cytoplasmic pool that is responsive to Wnt-FZD signaling (Fagotto et al., 1996; Sadot et al., 1998). As a result, the modulation of cadherin expression and function can indirectly regulate the Wnt-FZD signaling pathway through \(\beta\)-catenin. Because both cadherins and Wnt proteins have been demonstrated to regulate aspects of synapse formation, the interaction between these proteins also may play a critical role in the development of nervous system (Hall et al., 2000; Patapoutian & Reichardt, 2000; Tanaka et al., 2000).

2. The Wnt Pathway in Development and Metabolism

2.1 The Wnt Pathway, Stem Cells, and Development

The Wnt-FZD signaling pathway forms a critical component for the development of the brain, spinal cord, and the cardiovascular system (Table 1). Wnt can regulate the course of progenitor cells in various regions of the nervous system (Bronner-Fraser, 2004; Hirabayashi et al., 2004; Lee et al., 2004; Muroyama et al., 2004). Wnt pathway components that involve \(\beta\)-catenin and GSK-3\(\beta\) can control hippocampal and subventricular zone progenitor cell proliferation and differentiation (Adachi et al., 2007; Wexler et al., 2007). Modulation of \(\beta\)-catenin in the Wnt pathway also may be involved in the control of the orphan nuclear receptor Nurr1 that is vital for the development and maintenance of midbrain dopaminergic neurons (Kitagawa et al., 2007). The Wnt pathway, such as through Wnt1, also controls neuronal proliferation in the caudal midbrian region (Panhuysen et al., 2004). Even during periods of injury, such as during ischemia, Wnt signaling has recently been associated with neural stem cell proliferation (Wang et al., 2007b). However, abnormal Wnt signaling can lead to progenitor cell proliferation, but ultimately may not influence cell survival or differentiation (Chevallier et al., 2005).

In regards to the cardiovascular system, Wnt signaling has recently been shown to mediate the development of early blood and endothelial cells from human embryonic stem cells (Woll et al., 2007) (Table 1). Activation of the Wnt pathway through Wnt3a promotes the development of multipotential mesendodermal progenitor cells to eventually differentiate along endothelial, cardiac, and vascular smooth muscle lineages (Bakre et al., 2007). Wnt2 also has been found to influence progenitor cells to differentiate along endothelial and cardiac lineages (Wang et al., 2007a). Furthermore, canonical Wnt signaling fosters the expression of mammalian cardiac progenitors (Kwon et al., 2007) as well as right ventricular growth (Ai et al., 2007).
During cardiac development, Wnt9a has been found to stimulate β-catenin-responsive transcription in avian cardiac atrioventricular endocardial cushions and lead to cell proliferation (Person et al., 2005). It also has been shown that conditional targeting of APC, a protein that can down-regulate intracellular levels of β-catenin in the neural crest, yields apoptosis of cardiac neural crest cells, resulting in cardiac anomalies at birth (Hasegawa et al., 2002). The Wnt/β-catenin also assists with the aggregation of cardiomyocytes during development (Toyofuku et al., 2000). Recent work that has generated conditional β-catenin-deletion mutant animals in the proepicardium demonstrate that the epicardial β-catenin pathway is required for the development of the subepicardial space and the differentiation of epicardium-derived mesenchymal cells into coronary smooth muscle cells (Zamora et al., 2007). These studies suggest that Wnt signaling and β-catenin are required for proper development of cardiac tissue. Several studies also provide support for the ability of the Wnt system through GSK-3β to regulate cardiac development and hypertrophy (Hardt & Sadoshima, 2002). In addition, the BMP pathway appears to be vital for the specification of the first heart field, but that Wnt/β-catenin signaling regulates the second heart-field (Klaus et al., 2007). Other studies that examine β-catenin expression in the avian mesonephros, a transitory embryonic kidney that is used in the study of vascular development and degeneration, have shown that degenerating mesonephros and glomerular capillary tufts had significantly depressed β-catenin expression. These observations are in contrast to viable cells with prominent β-catenin expression, suggesting that β-catenin expression was linked to remodeling of the vascular system (Nacher et al., 2005).

Timing of events, temporal location, and non-canonical pathways also appear to be notable factors to mention. Inhibition of Wnt signaling can promote cardiac formation in the anterior lateral mesoderm, but active Wnt signaling in the posterior lateral mesoderm is required for blood development (Marvin et al., 2001). Activation of the Wnt/β-catenin pathway in the early phase during embryoid body (EB) formation enhances embryonic stem cell differentiation into cardiomyocytes, but activation of this pathway in the late phase after EB formation inhibits cardiomyocyte differentiation and enhances the expression of hematopoietic/vascular marker genes through suppression of BMP (Naito et al., 2006). Non-canonical Wnt pathways and antagonists of the Wnt pathway also play a role with cardiac development, such as with stromal vascular cells derived from the stromal vascular fraction of adipose tissue (Palpant et al., 2007) and embryonic stem cell differentiation into cardiomyocytes (Singh et al., 2007). In addition, Wnt11 can promote cardiomyogenic differentiation of human circulating endothelial progenitor cells through activating the non-canonical protein kinase C (PKC)-dependent signaling pathway (Koyanagi et al., 2005). A number of studies have demonstrated that several components of the Wnt-FZD signaling pathway also can oversee cell proliferation and migration during development in the nervous system. In Xenopus embryos, the Wnt-FZD signaling pathway has been shown to activate neuronal development through inhibition of bone morphogenetic protein (BMP) 4 expression (Baker et al., 1999). BMP 5 also is involved in dorsal pattern specification, which may play an important role in dorsal-ventral patterning of the developing brain which is ultimately under control of the Wnt-FZD pathway (Ellies et al., 2000; Golden et al., 1999). BMPs through Wnt signaling also can increase the number of tyrosine hydroxylase-positive locus coeruleus neurons (Holm et al., 2006). BMP and a Wnt-BMP signaling loop can regulate cell proliferation, migration, and axonal guidance of neurons in the developing nervous system (Chizhikov & Millen, 2005; Yeo & Gautier, 2004). It also appears that blockade of Wnt8 function, as shown by over-expression of a dominant negative Wnt8, can inhibit the expression of neural crest markers, suggesting that Wnt signaling pathway also is necessary for neural crest induction (LaBonne & Bronner-Fraser, 1998; Lewis et al., 2004). Other studies that employ gain-and loss-of-function for Wnt signaling have demonstrated that the Wnt-FZD signaling pathway plays a critical role either in neural crest induction or in the specification of...
the neural crest competence territory (Bastidas et al., 2004). Wnt genes, genes encoding FZD-Wnt receptors, or secreted FZD-related proteins and Tcf/Lef-1 transcription factors, also are expressed in postnatal mouse cerebral cortex, indicating that Wnt signaling represents a major cortical input during embryonic brain development (Shimogori et al., 2004). Furthermore, in models of C. elegans, the Wnt-FZD pathway may regulate the subcellular positioning of presynaptic terminals to determine synaptic connections in the nervous system (Klassen & Shen, 2007). Interestingly, the Wnt pathway may control only specific elements of development, such as cell adhesion, but not retinal neurogenesis (Fu et al., 2006).

Additional work demonstrates that autoregulation of the canonical Wnt/β-catenin signaling pathway can control midbrain development through the expression of transcription factor Tcf-4 isoforms and Wnt2b (Kunz et al., 2004). In addition, Wnt signaling can foster midbrain differentiation into dopaminergic neurons through GSK-3β modulation (Castelo-Branco et al., 2004). Lef1/Tcf proteins also regulate the generation of dentate gyrus granule cells and the development of the hippocampus (Galceran et al., 2000). Mouse embryos homozygous for a Lef1-lacZ fusion gene, which encodes a protein that not only is deficient in DNA binding, but also interferes with β-catenin-mediated transcriptional activation by other Lef1/Tcf proteins, are absent of the hippocampal structure. Other work demonstrates roles for DVL, Rac, and JNK signaling pathways during neuronal development. Wnt7b and DVL can activate Rac and JNK signaling pathways to promote dendritic branching in cultured hippocampal neurons, since application of dominant-negative Rac, administration of dominant-negative JNK, or inhibition of JNK activity can inhibit DVL-mediated dendritic growth (Rosso et al., 2005).

It is important to note that during development of the neuronal and cardiovascular systems, the modulation of apoptotic pathways by Wnt signaling is a critical component for the regulation of cell and tissue growth. Wnt signaling can either facilitate or prevent apoptosis depending upon the environmental stimuli. For example, Wnt proteins can regulate apoptosis within rhombomeres 3 and 5 in the developing hindbrain and in limb buds during vertebrate limb development to control growth of the hindbrain and limbs (Ellies et al., 2000; Grotewold & Ruther, 2002a, 2002b). In addition, sFRPs that function as antagonists of the Wnt-FZD pathway can also modulate apoptosis during development. For example, there exists a negative relationship between the expression of sFRP2 and the occurrence of apoptosis in rhombomeres 3 and 5. The over-expression of sFRP2 in the rhombencephalic neural crest can prevent the apoptosis of premigratory neural crest cells from rhombomeres 3 and 5 by inhibiting the expression of Wnt1 and BMP4. In contrast, depleting sFRP2 function or over-expressing Wnt1 in rhombomeres results in apoptosis (Ellies et al., 2000). sFRP2 also can function to inhibit Wnt3a expression during cardiomyogenesis as a feedback mechanism (Deb et al., 2007) and regulate myocardial tissue repair following ischemic injury (Mirotsou et al., 2007). The Wnt-β-catenin signaling pathway also is involved in the regulation of apoptotic cell loss during development and can prevent apoptosis through the regulation of β-catenin and Tcf/Lef. In β-catenin mutant embryos, the removal of β-catenin can lead to apoptotic loss of the hindbrain, the melanocyte lineage, neural crest cells, sensory neurons, and dorsal root ganglia (Brault et al., 2001; Hari et al., 2002). Over-expression of exogenous Wnt1 results in the protection of cells against c-Myc induced apoptosis through induction of β-catenin, cyclooxygenase-2, and Wnt1 induced secreted protein (WISP-1) (You et al., 2002).

### 2.2 The Wnt Pathway and Metabolic Disease

A body of recent work suggests that the Wnt signaling pathway has a significant role in cellular metabolism, especially in disorders that involve diabetes mellitus (DM). DM is a significant health concern for both young and older populations (Maiese et al., 2007a; Maiese et al., 2007c). Approximately 16 million individuals in the United States and more than 165 million individuals worldwide suffer from DM. By the year 2030, it is predicted that more than 360
million individuals will be afflicted with DM and its debilitating conditions (Wild et al., 2004). Type 2 DM represents at least 80 percent of all diabetics and is dramatically increasing in incidence as a result of changes in human behavior and increased body mass index (Laakso, 2001). Type 1 insulin-dependent diabetes mellitus accounts for only 5–10 percent of all diabetics (Maiese et al., 2007c), but is increasing in adolescent minority groups (Dabelea et al., 2007). Yet, the incidence of undiagnosed diabetes, impaired glucose tolerance, and fluctuations in serum glucose in the young raises further concerns (Jacobson et al., 2007). Individuals with impaired glucose tolerance have a greater than two times the risk for the development of diabetic complications than individuals with normal glucose tolerance (Harris & Eastman, 2000).

In regards to the vascular and nervous systems, patients with DM can develop severe neurological and vascular disease (Donahoe et al., 2007) that can lead to an increased risk for cognitive decline (Chong et al., 2005d; Li et al., 2006a; Schnaiter Beeri et al., 2004). Disease of the nervous system can become the most debilitating complications for DM and affect sensitive cognitive regions of the brain, such as the hippocampus that modulates memory function, resulting in significant functional impairment and dementia (Awad et al., 2004). DM also has been found to increase the risk for vascular dementia in elderly subjects (Schneider Beeri et al., 2004; Xu et al., 2004) as well as potentially alter the course of Alzheimer’s disease. Although some studies have found that diabetic patients may have less neuritic plaques and neurofibrillary tangles than non-diabetic patients (Beeri et al., 2005), contrasting work suggests a modest adjusted relative risk of Alzheimer’s disease in patients with diabetes as compared with those without diabetes to be 1.3 (Luchinger et al., 2001). Furthermore, costs to care for cognitive impairments resulting from diabetes that can mimic Alzheimer’s disease can approach $100 billion a year (Maiese & Chong, 2004; McCormick et al., 2001; Mendiondo et al., 2001).

Interestingly, the development of insulin resistance and the complications of DM in the nervous and vascular systems can be the result of cellular oxidative stress (Maiese et al., 2007a; Maiese et al., 2007c). In patients with DM, elevated levels of ceruloplasmin are suggestive of increased reactive oxygen species (Memisogullari & Bakan, 2004) and acute glucose fluctuations may promote oxidative stress (Monnier et al., 2006). Hyperglycemia can lead to increased production of reactive oxygen species in endothelial cells, liver and pancreatic β-cells (Ceriello et al., 1996; Ihara et al., 1999; Ling et al., 2003; Yano et al., 2004). Prolonged duration of hyperglycemia is not necessary to lead to oxidative stress injury, since even short periods of hyperglycemia, generate reactive oxygen species, such as in vascular cells (Yano et al., 2004). Recent clinical correlates support these experimental studies to show that acute glucose swings in addition to chronic hyperglycemia can trigger oxidative stress mechanisms during type 2 DM, illustrating the importance for therapeutic interventions during acute and sustained hyperglycemic episodes (Monnier et al., 2006).

The preservation of cellular energy reserves is dependent upon the maintenance of mitochondrial integrity during DM (Newsholme et al., 2007). For example, chronic exposure to elevated levels of free fatty acids can increase reactive oxygen species production in cells and has been shown to lead to mitochondrial DNA damage and impaired pancreatic β-cell function (Rachek et al., 2006). In patients with type 2 DM, skeletal muscle mitochondria have been described to be smaller than those in control subjects (Kelley et al., 2002). Furthermore, a decrease in the levels of mitochondrial proteins and mitochondrial DNA in adipocytes has been correlated with the development of type 2 DM (Choo et al., 2006). Insulin resistance in the elderly also has been associated with elevation in fat accumulation and altered mitochondrial oxidative and phosphorylation activity (Petersen et al., 2003; Pospisilik et al., 2007).
Current studies suggest that abnormalities in the Wnt signaling pathways, such as with transcription factor 7-like 2 gene, may impart increased risk for type 2 DM in some populations (Grant et al., 2006; Lehman et al., 2007; Scott et al., 2006) as well as have increased association with obesity (Guo et al., 2006). Additional work has described the expression of Wnt5b in adipose tissue, the pancreas, and the liver in diabetic patients, suggesting a potential regulation of adipose cell function (Kanazawa et al., 2004). Clinical observations in patients with coronary artery disease and the combined metabolic syndrome with hypertension, hyperlipidemia, and DM have observed impaired Wnt signaling through a missense mutation in LRP-6 (Mani et al., 2007) (Table 2). Experimental studies in mice with hyperglycemia through a high fat diet also demonstrate increased expression of some Wnt family members, such as Wnt3a and Wnt7a (Al-Aly et al., 2007). In addition, intact Wnt family members may offer glucose tolerance and increased insulin sensitivity (Wright et al., 2007) as well as protect glomerular mesangial cells from elevated glucose induced apoptosis (Lin et al., 2006). Animals that over-expressed Wnt10b and were placed on a high-fat diet had a reduction in bodyweight, hyperinsulinemia, triglyceride plasma levels, and improved glucose homeostasis (Aslanidi et al., 2007).

These clinical and experimental observations for the Wnt pathway in conditions associated with hyperglycemia and DM suggest a potential protective cellular mechanism for Wnt. Recent in vitro studies demonstrate that the Wnt1 protein is necessary and sufficient to provide cellular protection during elevated glucose exposure (Chong et al., 2007c). Administration of exogenous Wnt1 protein can significantly prevent apoptotic endothelial cell (EC) injury during elevated glucose exposure. Interestingly, this protection by Wnt1 can be regulated by the growth factor and cytokine erythropoietin (EPO) (Maiese et al., 2004, 2005b; Nangaku & Fliser, 2007). Through the Wnt pathway, EPO may offer an attractive therapy to maintain proper cellular metabolism and mitochondrial membrane potential during conditions of oxidative stress and DM. In cell culture and animal studies, EPO is cytoprotective during elevated glucose (Chong et al., 2007c) and can block apoptotic DNA degradation during elevated glucose similar to other models of oxidative stress in cardiac and vascular cell models (Avasarala & Konduru, 2005; Chong et al., 2002b, 2003a; Chong & Maiese, 2007a; Moon et al., 2006). EPO can at times enhance tissue function (Ben-Dor et al., 2007) and is closely related to the maintenance of mitochondrial membrane potential ($\Delta \Psi_m$) (Li et al., 2004a). Loss of $\Delta \Psi_m$ through the opening of the mitochondrial permeability transition pore represents a significant determinant for cell injury and the subsequent induction of apoptosis (Leuner et al., 2007; Maiese & Chong, 2004). EPO has the capacity to prevent the depolarization of the mitochondrial membrane that also affects the release of cytochrome c (Chong et al., 2002b; Chong et al., 2003d; Miki et al., 2006). With the Wnt pathway, EPO maintains the expression of Wnt1 during elevated glucose exposure and prevents loss of Wnt1 expression that would normally occur in the absence of EPO during elevated glucose. In addition, blockade of Wnt1 with a Wnt1 antibody can neutralize the protective capacity of EPO, illustrating that Wnt1 is a critical component in the cytoprotection of EPO during elevated glucose exposure (Chong et al., 2007c).

3. The Wnt Pathway in Neurodegeneration, Vascular Disease, and Cardiac Dysfunction

3.1 Wnt and Disease of the Nervous System

The Wnt pathway can influence both acute and chronic disease processes of the nervous system. For example, experimental models of behavior suggest that the ability to tolerate stressful environments may be associated with the expression of Wnt2 (Krishnan et al., 2007). Other work suggests that loss of Wnt signaling may contribute to retinal neurodegeneration, since retinal degeneration with the progressive loss of photoreceptors during retinitis pigmentosa has been associated with increased secretion of the Wnt inhibitory protein FZD-related
protein-2 (Jones et al., 2000). Studies have also demonstrated that a mutation in the membrane-type FZD-related protein gene may be involved in retinal photoreceptor degeneration (Kameya et al., 2002).

In relation to cognitive function, Wnt has been demonstrated in the brains of individuals affected by neuropsychiatric disorders (Miyaoka et al., 1999). In models of frontotemporal dementia, the Wnt pathway can be up-regulated early during the onset of the disease (Wiedau-Pazos et al., 2007). It is conceivable that this increased expression of Wnt may improve memory function similar to work that has demonstrated improved cognition with agents such as lithium chloride that enhance Wnt activity have shown (De Ferrari et al., 2003). Genetic analysis also suggests that LRP-6 variants of the Wnt pathway may be associated with late onset Alzheimer’s disease (De Ferrari et al., 2007) and that up-regulation of the Wnt pathway such as with agents as cannabidiol may provide alternative treatments for Alzheimer’s disease (Esposito et al., 2006a) (Table 2). Although it is unclear whether Wnt expression has a direct role in the development of neuropsychiatric or dementia disorders, the Wnt pathway has been tied to several of the pathological components of Alzheimer’s disease (Li et al., 2005, 2006c). The production of β-amyloid (Aβ) peptide aggregates composed of a 39–42 amino acid peptides and the accumulation of intracellular neurofibrillary tangles are considered to be two critical pathological mechanisms that lead to Alzheimer’s disease. In Drosophila models of neurodegeneration, Wnt can lead to neurofibrillary pathology (Jackson et al., 2002).

The proteolytic processing of amyloid precursor protein (APP) during Alzheimer’s disease has been closely linked to the Wnt pathway through presenilin 1 (PS1) and DVL. APP cleaves β-amyloid into products that include a 40-residue peptide and a 42-residue peptide (Aβ₁₋₄₂). However, it is Aβ₁₋₄₂ that is considered to be the β-amyloid product that most directly leads to Alzheimer’s disease and apoptotic injury (Chong et al., 2005e; Maiese & Chong, 2004). Wnt may regulate APP isoform expression (Morin et al., 2004). In addition, PS1 is required for the processing of APP and has been shown to down-regulate Wnt signaling and interact with β-catenin to promote its turnover (Soriano et al., 2001). Using a familial Alzheimer’s disease-associated PS-1 mutant, PS-1 (L286V), other studies have shown that pharmacological inhibition of T cell factor/β-catenin/cAMP-response element-binding protein (CREB)-binding protein (CBP)-mediated transcription restores normal neurite outgrowth, illustrating the integration of the Wnt in the PS pathway (Teo et al., 2005). DVL also can regulate the α-secretase cleavage of APP through protein kinase C/mitogen-activated protein kinase dependent pathways, increasing production of soluble APP (Mudher et al., 2001). Furthermore, over-expression of mouse DVL-1 and –2 inhibits GSK-3β mediated phosphorylation of tau protein and may thus prevent formation of neurofibrillary tangles during Alzheimer’s disease (Wagner et al., 1997).

Current studies also have examined the ability of Wnt to directly reduce β-amyloid toxicity. Investigations with lovastatin as an extension of prior clinical work that suggests that a lower prevalence of Alzheimer’s disease can occur during statin administration show that this agent can reduce β-amyloid production and cellular injury through increased β-catenin activity and the inhibition of GSK-3β (Salins et al., 2007). In addition, the pathways controlled by Wnt1 appear to be critical for neuronal protection during β-amyloid exposure against genomic DNA degradation, membrane PS exposure, and microglial activation (Chong et al., 2007a). The neuroprotective attributes of Wnt1 against β-amyloid are lost during gene silencing of Wnt1 protein expression. More importantly, Wnt 1 protection is dependent upon protein kinase B (Akt) activity and the inhibition of GSK-3β with the cellular translocation β-catenin to the nucleus (Chong et al., 2007a) (Figure 2).
3.2 Wnt, Vascular Integrity, and Immunity

In many respects, the ability of Wnt to foster new vascular growth is complimentary to the ability of Wnt to afford protection in the nervous system. Several Wnt family members can control endothelial cell development (Woll et al., 2007), proliferation, and migration (Cheng et al., 2008). New capillary formation from pre-existing vessels into an avascular area is a process known as angiogenesis (Chong et al., 2002a). Angiogenesis is present during embryogenesis, during menstruation, and during pathological processes that involve wound healing, chronic inflammation, and tumor growth (Risau, 1997). In several vascular cell populations, Wnt signaling plays a significant part in the modulation of new vessel formation. Several Wnt ligands, such as Wnt2, Wnt5a, Wnt7a, and Wnt10b, are expressed endogenously in ECs and vascular smooth muscle cells. Wnt receptors that involve Fzd1, Fzd2, Fzd3, and Fzd5, as well as cysteine-rich 61 that contains Wnt-induced secreted proteins-1, 2 and 3 are also expressed in these cell populations for Wnt to exert a direct biological effect (Brigstock, 2002; Li et al., 2006c). For example, mice deficient in Wnt2 and Fzd5 display vascular abnormalities that include defective placental vasculature as well as embryonic lethal mutations (Ishikawa et al., 2001). Antagonism of the Wnt system, such as through sFRP expression also blocks endothelial cell proliferation (Ezan et al., 2004). In contrast, over-expression of Wnt1 can lead to the proliferation of cultured primary ECs, increase the free pool of β-catenin, and activate transcription through Tcf/Lef, suggesting that the Wnt-FZD signaling pathway is closely involved in the proliferation of ECs (Wright et al., 1999). Yet, Wnt1 signaling also can have a regulatory role, such as during the proliferation of umbilical vein ECs, to block further growth through mechanisms that involve cell-cell contact (Cheng et al., 2003). Studies with mice homozygous for the deletion of the Wnt receptor ligand Fzd5 that can synergize with Wnt2, Wnt5a, and Wnt10b lead to embryos that die in utero approximately 10 days post coitum as a result of defects in yolk sac angiogenesis, supporting a critical role for Wnt during embryonic vascular development (Ishikawa et al., 2001). In contrast, mice heterozygotes were found to be viable, fertile and appear normal. In disorders that involve failure of peripheral retinal vascularization, mutations in Fzd4, a gene encoding the Wnt receptor FZD-4, are believed to account for the vascular failure. Studies have shown that injection of only wildtype Fzd4, but not mutated Fzd4, into Xenopus embryos can activate CamKII and PKC, components of the Wnt/Ca²⁺ signaling pathway, to control retinal angiogenesis (Robitaille et al., 2002), supporting that Wnt-FZD signaling pathway broadly controls vascular development and function in a number of organ systems. In addition, FrzA, as a member of secreted FZD-related protein, can increase migration and tube formation of ECs to result in enlarged, longer, and mature of vessels, further supporting the necessity of the Wnt- FZD signaling pathway during development of the vasculature (Dufourcq et al., 2002) (Table 2).

In addition to vascular development, the Wnt pathway participates in inflammatory cell control and the regulation of vascular injury. In fact, the ability of the Wnt pathway to modulate inflammatory cell activity can ultimately impact upon cell survival and longevity since activated immune cells can lead to the phagocytic removal of both neurons and vascular cells (Chong et al., 2005a; Chong et al., 2004a; Kang et al., 2003b). During inflammation, microglial cells require the activation of intracellular cytoprotective pathways (Chong et al., 2007b; Li et al., 2006b) to proliferate and remove injured cells (Li et al., 2005; Mallat et al., 2005). Subsequently, microglia can form a barrier for the removal of foreign microorganisms from the central nervous system and promote tissue repair during neuronal and vascular cell injury (Chong et al., 2007b; Dringen, 2005). Yet, microglia also may lead to cellular damage through the generation of reactive oxygen species (Maiese & Chong, 2004; Sankarapandian et al., 1998) and through the production of cytokines (Benzing et al., 1999; Mehlhorn et al., 2000). During injury to cells, activation of microglia can parallel the induction of cellular apoptosis and correlate well with the severity of an ischemic insult (Chong et al., 2004a; Kang et al., 2003a, 2003b). Furthermore, microglial activation has been associated with several
neurodegenerative disorders, such as Alzheimer’s disease with the co-localization of microglia and amyloid plaque development (Sheng et al., 1997).

Given the significant impact that inflammatory cells may play during oxidative stress and cell injury, it becomes essential to understand the role of Wnt during inflammatory cell activation. Early work has shown that Wnt Transcripts for Wnt 4, 7b, 10b and 13 were up-regulated in macrophages during human colorectal cancer (Smith et al., 1999). Subsequent work has suggested that Wnt family members, such as Wnt7b in macrophages, may be responsible for the apoptotic cell death of adjacent vascular cells (Lobov et al., 2005) and that inflammatory cells require components of the Wnt signaling pathway to maintain cellular integrity (Chong et al., 2007b). Interestingly, the canonical Wnt pathway can increase monocyte adhesion to ECs (Lee et al., 2006a) and control transendothelial migration of monocytes (Tickenbrock et al., 2006). Wnt also can influence matrix metalloproteinase (MMP) 2 and MMP9 expression to support T cell migration through basement membranes (Wu et al., 2007a). Wnt1 has recently been shown to possess a unique capacity to not only prevent early apoptotic membrane PS exposure, but also directly modulate inflammatory microglial activation and proliferation (Chong et al., 2007a) that can lead to cellular engulfment and removal (Chong et al., 2005a).

Investigations that employ vascular cell injury models also support a direct cytoprotective role for the Wnt signaling pathway that may be independent from inflammatory cell modulation. In a rat aorta balloon injury model, the FZD receptor (rFrz) genes, rFrz1 and rFrz 2, have been shown to be transiently down-regulated as early as one hour following balloon injury. Yet, Frzb-1, a secreted protein that acts as an antagonist of Wnt signaling, can be increased and appears to coincide with the arrest of aortic smooth muscle cell proliferation (Mao et al., 2000). Similarly, the secreted protein FrzA can be elevated in ECs during traumatic manipulation and subsequently block the proliferation of ECs (Duplaa et al., 1999). In regards to apoptotic vascular injury, it has been shown that within eight hours following EC shear stress, expression of β-catenin is significantly increased at the cell-cell junctions of ECs (Noria et al., 1999). In addition, transfection of a degradation-resistant β-catenin into rat vascular smooth muscle cells can prevent apoptotic vascular cell injury. Furthermore, use of a dominant negative Tcf-4 transgene lacking the β-catenin binding domain, Tcf4 (N31), can eliminate cytoprotection from the Wnt pathway (Wang et al., 2002). Similar to arterial vessels, the Wnt signaling pathway also plays a role during venous injuries. In a crush injury vein model, Wnt5a can have increased expression that may be beneficial to overcome antagonists of the Wnt pathway (Price et al., 2004). In brain ECs, endogenous activation of Wnt1 also may offer a minimum level of protection during elevated glucose exposure, since application of a Wnt1 antibody results in a slight increase in EC injury. Furthermore, administration of exogenous Wnt1 protein significantly increases EC survival and prevents apoptotic EC degeneration during elevated glucose exposure. More importantly, administration of a Wnt1 antibody in the presence of exogenous Wnt1 application can neutralize the protective capacity of Wnt1, illustrating that Wnt1 is an important component in the cytoprotection of ECs during elevated glucose exposure (Chong et al., 2007c) (Table 2).

3.3 Wnt and Cardiac Dysfunction

During the complicated process of wound healing in the heart, changes in components of the Wnt- FZD signaling pathway, such as Wnt (Barandon et al., 2003), FZD (van Gijn et al., 2001), DVL-1 (Chen et al., 2004), GSK-3β (El Jamali et al., 2004), β-catenin (Bergmann et al., 2004), and sFRP (Barandon et al., 2003) can occur. For example, during myoblast proliferation and migration following myocardial infarction, elevated expression of FZD genes including FZD 1, 2, 5, 6, 7, 8, and 10 have been identified during heart remodeling. The over-expression of some FZD genes may be associated with reduction in infarct size and the prevention of cardiac rupture to improve cardiac function (Barandon et al., 2003). It is

Pharmacol Ther. Author manuscript; available in PMC 2009 April 1.
important to note that different members of the Wnt family may contribute to distinct events during cardiac injury. Both Wnt8a and Wnt10b are up-regulated following myocardial infarction while Wnt7b is down-regulated to undetectable levels during this period (Barandon et al., 2003). Additional work also has demonstrated that β-catenin is translocated from the plasma membrane to the cytoplasm of ECs following the expression of DVL during the phase of the neovascularization after myocardial infarction (Blankesteijn et al., 2000). Furthermore, over-expression of antagonists of the Wnt/FZD pathway can reverse the benefit of treatments such as ischemic preconditioning and minimize β-catenin and Akt activity (Barandon et al., 2005). Interestingly, mice heterozygous for the loss of β-catenin (homozygous mice die at birth) have no structural or functional abnormalities, but suffer from significantly decreased heart weight and heart weight/body weight ratio during transverse aortic constriction (Qu et al., 2007). These data suggest that the Wnt system and its components that involve β-catenin can prevent cardiomyocyte injury and preserve potential myocardial function (Table 2).

Furthermore, the expression of another Wnt component, DVL-1, appears to have a vital role during cardiac injury. The expression of DVL-1 mRNA and cytoplasmic DVL-1 protein are significantly enhanced within days in myofibroblasts, vascular ECs, and smooth muscle cells of newly formed and pre-existing blood vessels in the region of a myocardial infarction (Chen et al., 2004). In addition, mice without DVL-1 demonstrate a benefit from pressure overload cardiac hypertrophy that is mediated through Akt and GSK-3β (van de Schans et al., 2007).

In addition to FZD, DVL-1, and several Wnt genes, other members of the Wnt signaling cascade also appear to have relevant roles during myocardial injury. Expression of sFRP3 and sFRP4 in failing human ventricular myocardium is increased when compared to donor hearts. This increased expression of sFRP is associated with the expression of the pro-apoptotic Fas proteins, but inversely linked to the expression of the anti-apoptotic protein Bcl-xL (Schumann et al., 2000). Other studies illustrate that cardiac rupture following myocardial infarction is correlated with decreased levels of β-catenin in cardiomyocytes (Blankesteijn et al., 1999). The lack of β-catenin in the adherence junctions of cardiomyocytes may lead to impaired structural integrity of the heart, since β-catenin may play a vital role in a structural adaptor protein linking cadherins to the actin cytoskeleton in cell-cell adhesion (Ligon et al., 2001). Yet, the role of β-catenin during cardiac infarction is not entirely clear, since cytosolic β-catenin exists in vascular ECs and smooth muscle cells that reside in the area of myocardial infarction (Barandon et al., 2003). Pathological cardiac hypertrophy also may be dependent upon modulation of the Wnt pathway. In volume-overloaded rabbit hearts, cardiac hypertrophy is accompanied by suppressed mRNA expression of β-catenin (Itoh et al., 2002). The suppressed levels of β-catenin may be a result of increased GSK-3β activity. Other work has demonstrated that inhibition of GSK-3β by Akt through phosphorylation of a serine residue at position 9 can play an important role in the development of cardiac hypertrophy (Haq et al., 2000; Hardt & Sadoshima, 2002) especially during pressure overload (van de Schans et al., 2007).

4. Wnt Governs Vital Cytoprotective Pathways
4.1 Wnt, Oxidative Stress, and Apoptosis

Wnt signaling controls a variety of signal transduction pathways for cytoprotection that can involve protein kinase B, caspases, forkhead transcription factors, GSK-3β, and nuclear factor κB. Intimately associated with Wnt signaling pathways that control cellular survival and longevity are the injury mechanisms associated with apoptosis (Figure 3). Oxidative stress occurs as a result of the development of reactive oxygen species that consist of oxygen free radicals and additional chemical entities.

Oxygen consumption in organisms, or at least the rate of oxygen consumption in organisms, has intrigued a host of investigators and may have had some of its original origins with the
work of Pearl. Pearl proposed that increased exposure to oxygen through an increased metabolic rate could lead to a shortened life span (Pearl, 1928). Subsequent work by multiple investigators has furthered this hypothesis by demonstrating that increased metabolic rates could be detrimental to animals in an elevated oxygen environment (Muller et al., 2007). When one examines more current work, oxygen free radicals and mitochondrial DNA mutations have become associated with oxidative stress injury, aging mechanisms, and accumulated toxicity for an organism (Yui & Matsuura, 2006).

Oxygen free radicals can be generated in elevated quantities during the reduction of oxygen and subsequently lead to cell injury and apoptosis. Reactive oxygen species can involve superoxide free radicals, hydrogen peroxide, singlet oxygen, nitric oxide (NO), and peroxynitrite (Chong et al., 2005d). Most species are produced at low levels during normal physiological conditions and are scavenged by endogenous antioxidant systems that include superoxide dismutase (SOD), glutathione peroxidase, catalase, and small molecule substances such as vitamins C and E. Other closely linked pathways to oxidative stress may be tempered by different vitamins, such as vitamin D₃ (Regulska et al., 2007) and the amide form of niacin or vitamin B₃, nicotinamide (Chlopicki et al., 2007; Chong et al., 2002c; Feng et al., 2006; Hara et al., 2007; Ieraci & Herrera, 2006; Lin et al., 2000; Maiese & Chong, 2003).

Oxidative stress leads to the destruction of multiple cell types that include neuronal and vascular cells (Chong et al., 2006a; De Felice et al., 2007; Lin & Maiese, 2001). More importantly, it has recently been shown that genes involved in the apoptotic process are replicated early during processes that involve cell replication and transcription, suggesting a much broader role for these genes than originally anticipated (Cohen et al., 2007). Apoptotic induced oxidative stress in conjunction with processes of mitochondrial dysfunction can contribute to a variety of disease states such as diabetes, ischemia, general cognitive loss, Alzheimer’s disease, and trauma (Chong et al., 2005d, 2005e; Harris et al., 2007; Leuner et al., 2007; Okouchi et al., 2007). Oxidative stress can lead to apoptosis in a variety of cell types that involve neurons, ECs, cardiomyocytes, and smooth muscle cells through multiple cellular pathways (Chong et al., 2004a; Chong et al., 2007b; Harris et al., 2007; Kang et al., 2003b; Karunakaran et al., 2007; Verdaguer et al., 2007).

Externalization of membrane phosphatidylserine (PS) externalization is an early event during cell apoptosis (Maiese et al., 2000; Mari et al., 2004) and can become a signal for the phagocytosis of cells (Chong et al., 2005a; Li et al., 2006b; Lin & Maiese, 2001). The loss of membrane phospholipid asymmetry leads to the externalization of membrane PS residues and assists microglia to target cells for phagocytosis (Chong et al., 2003c; Kang et al., 2003a, 2003b; Maiese & Chong, 2003; Mallat et al., 2005). This process occurs with the expression of the phosphatidylserine receptor (PSR) on microglia during oxidative stress (Li et al., 2006a, 2006c), since blockade of PSR function in microglia prevents the activation of microglia (Chong et al., 2003b; Kang et al., 2003a). As an example, externalization of membrane PS residues occur in neurons during anoxia (Maiese, 2001; Maiese & Boccone, 1995; Vincent & Maiese, 1999a), nitric oxide exposure (Chong et al., 2003c; Maiese et al., 1997), and during the administration of agents that induce the production of reactive oxygen species, such as 6-hydroxydopamine (Salinas et al., 2003). Membrane PS externalization on platelets also has been associated with clot formation in the vascular system (Leytin et al., 2006).

The cleavage of genomic DNA into fragments (Maiese et al., 1999; Maiese & Vincent, 2000a, 2000b) is considered to be a later event during apoptotic injury (Chong et al., 2004b). Several enzymes responsible for DNA degradation have been differentiated and include the acidic, cation independent endonuclease (DNase II), cyclophilins, and the 97 kDa magnesium-dependent endonuclease (Chong et al., 2005d; Chong & Maiese, 2007b). Three separate endonuclease activities are present in neurons that include a constitutive acidic cation-
independent endonuclease, a constitutive calcium/magnesium-dependent endonuclease, and an inducible magnesium dependent endonuclease (Vincent & Maiese, 1999b; Vincent et al., 1999a).

During oxidative stress, mitochondrial membrane transition pore permeability also is increased (Chong et al., 2003a; Di Lisa et al., 2001; Kang et al., 2003b; Lin et al., 2000), a significant loss of mitochondrial NAD$^+$ stores occurs, and further generation of superoxide radicals leads to cell injury (Chong et al., 2005f; Maiese & Chong, 2003). In addition, mitochondria are a significant source of superoxide radicals that are associated with oxidative stress (Chong et al., 2005d; Maiese & Chong, 2004). Blockade of the electron transfer chain at the flavin mononucleotide group of complex I or at the ubiquinone site of complex III results in the active generation of free radicals which can impair mitochondrial electron transport and enhance free radical production (Chong & Maiese, 2007b; Li et al., 2006a). Furthermore, mutations in the mitochondrial genome have been associated with the potential development of a host of disorders, such as hypertension, hypercholesterolemia, and hypomagnesemia (Li et al., 2004b; Wilson et al., 2004). Reactive oxygen species also may lead to cellular acidosis and subsequent mitochondrial failure (Chong et al., 2005e). Disorders, such as hypoxia (Roberts & Chih, 1997), diabetes (Cardella, 2005; Kratzsch et al., 2006), and excessive free radical production (Ito et al., 1997; Vincent et al., 1999a, 1999b) can result in the disturbance of intracellular pH. When one considers the potential of Wnt pathways to foster cell development and survival, Wnt signaling may offer new therapeutic avenues against oxidative stress that leads to both early and late apoptotic stages in several disorders.

4.2 Wnt, Akt, and Caspases

One attractive pathway that may work in concert with Wnt to maintain cell survival and block inflammatory cell activation involves protein kinase B, or Akt (Chong et al., 2007a; Chong et al., 2007c; Li et al., 2006c; Speese & Budnik, 2007). Phosphorylation of Akt in conjunction leads to its activation and protects cells against genomic DNA degradation and membrane PS exposure (Chong et al., 2003a, 2003b; 2003d). Up-regulation of Akt activity during multiple injury paradigms, such as vascular and cardiomyocyte ischemia (Miki et al., 2006; Parsa et al., 2003), free radical exposure (Chong et al., 2003b; Matsuzaki et al., 1999), N-methyl-D-aspartate toxicity (Dzietko et al., 2004), hypoxia (Chong et al., 2002b; Zhang et al., 2007), β-amyloid toxicity (Chong et al., 2005c; Du et al., 2004; Nakagami et al., 2002), heat exposure (Shein et al., 2007), DNA damage (Chong et al., 2002b, 2004a; Henry et al., 2001; Kang et al., 2003a), and oxidative stress (Chong et al., 2004a; Kang et al., 2003a, 2003b) increases cell survival. Cytoskeleton through Akt also can involve control of inflammatory cell activation (Chong et al., 2003a; Kang et al., 2003a, 2003b), transcription factor regulation (Chong & Maiese, 2007a), maintenance of mitochondrial membrane potential ($\Delta \Psi_m$), prevention of cytochrome c release (Chong et al., 2003a, 2003b; Chong et al., 2003d), and blockade of caspase activity (Chong et al., 2002b, 2003a, 2003b).

Evidence for the dependence of Wnt on the Akt pathway can be drawn from a variety of cell populations (Chong et al., 2005b). For example, neuronal cell differentiation that is dependent upon Wnt signaling and trophic factor induction is blocked during the repression of Akt activity (Fukumoto et al., 2001), differentiation of cardiomyocytes does not proceed without Akt activation, (Naito et al., 2005) Wnt has been shown in preadipocytes to increase Akt phosphorylation (Longo et al., 2002), and the Wnt-induced secreted protein in a fibroblast cell line uses Akt to block apoptotic death (Su et al., 2002). sFRP2, which can modulate Wnt signaling, also employs Akt for cardiac tissue repair (Mirotou et al., 2007). Reduction in tissue injury during pressure overload cardiac hypertrophy also is linked to Akt activation (van de Schans et al., 2007) and the benefits of cardiac ischemic preconditioning appear to rely upon Akt (Barandon et al., 2005). In the neuronal system, Wnt over-expression can independently
increase the phosphorylation and the activation of Akt to promote neuronal protection. Inhibition of the phosphatidylinositol 3-kinase (PI 3-K) pathway or gene silencing of Akt expression prevents Wnt from blocking apoptotic injury and microglial activation (Chong et al., 2007a).

Modulation of Akt activity ultimately controls the apoptotic pathways of the caspase family. Caspases are a family of cysteine proteases that are synthesized as inactive zymogens which are proteolytically cleaved into subunits at the onset of apoptosis (Li et al., 2006a; Maiese et al., 2005a; Okouchi et al., 2007). The apoptotic-associated caspases include initiator caspases, such as caspase 2, 8, 9, and 10, that activate downstream effector caspases, resulting in an amplification of cascade activity. The initiator caspases consist of long N-terminal prodomains that contain caspase recruitment domains (CARDs) in caspase 2 and caspase 9 or death effector domains (DEDs) in caspase 8 and caspase 10 (Hofmann et al., 1997). The effector caspases consist of caspase 3, 6, and 7 that function to directly cleave crucial cellular protein substrates to result in cell destruction.

The caspases 1 and 3 have each been linked to the apoptotic pathways of genomic DNA cleavage and cellular membrane PS exposure (Chong et al., 2003a; Chong et al., 2003d; Takahashi et al., 1999). These caspases, in addition to caspase 8 and 9, are also tied to the direct activation and proliferation of microglia (Chong et al., 2003b; Kang et al., 2003a, 2003b). Caspase 1 is believed to be principally responsible for the externalization of membrane PS residues in several cell systems that can subsequently activate microglial phagocytosis (Chong et al., 2005a; Chong et al., 2004a; Kang et al., 2003b). Furthermore, caspase 9 is activated through a process that involves the cytochrome c-apoptotic protease-activating factor-1 (Apaf-1) complex (Chong et al., 2003a; Chong et al., 2005d; Kang et al., 2003a). In addition, caspase 8 serves as an upstream initiator of executioner caspases, such as caspase 3, and also leads to the mitochondrial release of cytochrome c (Engels et al., 2000; Stegh et al., 2002). Following caspase 8 and caspase 9 activation, caspase 3 directly leads to genomic DNA degradation.

In reference to the Wnt pathway and caspase activity, loss of Wnt4 and Wnt5a expression during elevated glucose in mesangial cells results in elevated caspase 3 activity and apoptotic cell death (Lin et al., 2006). Furthermore, reduction in caspase 9 activity by the Wnt pathway (Chen et al., 2001) and the prevention of cytochrome c release with caspase pathway activation (You et al., 2002) has been attributed to the resistance of cells to cancer therapeutics designed to induce apoptosis. Other members of the Wnt pathway that are mutated in disease, such as the APC gene during colonic polyp progression, can suppress caspase 3, 7, and 9 activities to prevent apoptotic demise of colonic polyps (Chen et al., 2003). In patients with Alzheimer’s disease, observation of Wnt pathway impairment and the increased phosphorylation of beta-catenin that can lead to its degradation has been suggested as a possible mechanism of pathology that is associated with elevated caspase 3 activity (Ghanevati & Miller, 2005).

### 4.3 Wnt and Forkhead Transcription Factors

As a central regulatory protein, Akt controls the activity and function of a number of robust pathways such as the mammalian forkhead transcription factor family that oversees processes that can involve cell metabolism, hormone modulation, and apoptosis (Cuesta et al., 2007; Maiese et al., 2007a; Maiese et al., 2007b). The mammalian forkhead transcription factor family preferentially bind to the core consensus DNA sequence 5′-TTGTTTAG-3′, the forkhead response element (Chong et al., 2005d; Chong et al., 2004c; Wijchers et al., 2006). The first member of this family was the *Drosophila melanogaster* gene *Fork head*. Since this time, greater than 100 forkhead genes and 19 human subgroups are known to exist that extend from FOXA to FOXS (Maiese et al., 2007b; Wijchers et al., 2006). The forkhead box (FOX) family of genes is characterized by a conserved forkhead domain commonly noted as a
“forkhead box” or “winged helix” as a result of the butterfly-like appearance on X-ray crystallography (Clark et al., 1993) and nuclear magnetic resonance (Jin et al., 1998). All Fox proteins contain the 100-amino acid winged helix domain, but it should be noted that not all winged helix domains are Fox proteins (Larson et al., 2007).

FOXO3a is one member of the forkhead family of transcription factors that exemplifies the ability to function as a versatile target for a number of disorders (Maiese et al., 2007b). Akt controls the “pro-apoptotic” forkhead transcription factor FOXO3a by inhibiting the nuclear translocation of FOXO3a that would normally activate the transcription of apoptotic nuclear genes (Chong & Maiese, 2007a). As a result, control of FOXO3a is considered to be a viable therapeutic target for agents such as metabotropic glutamate receptors (Chong et al., 2006b) and NAD+ precursors (Chong et al., 2004c; Li et al., 2006a, 2006b) to increase cell survival. In addition, FOXO3a interfaces with several pathways that regulate cellular lifespan (Lehtinen et al., 2006) and function to control neoplastic growth (Li et al., 2007).

If one then considers the role of forkhead transcription factors in the Wnt pathway, early work has shown that FoxD3 is activated by the Wnt pathway and inhibited by BMP signaling to control neural plate development (Pohl & Knochel, 2001). Other forkhead family members also rely upon the Wnt pathway for cellular proliferation and function. FoxI1 activates the Wnt/β-catenin pathway to increase extracellular proteoglycans, promote gastrointestinal cell proliferation (Perreault et al., 2001), and possibly foster carcinogenesis (Perreault et al., 2005). Yet, the Wnt pathway also utilizes forkhead members to regulate cellular function and can activate FoxN1 for regulatory control of thymic function (Balciunaite et al., 2002). In other examples of cell development, Wnt signaling has been shown to rely upon Foxf1 and Foxf2 during intestinal maturation in murine models (Ormestad et al., 2006). In addition, Foxa2 may be a significant component during in early anterior-posterior axis polarization (Kimura-Yoshida et al., 2007). Interestingly, β-catenin that is believed to function independently from other Wnt signaling pathways has been shown to bond to FOXO and enhance its transcriptional activity (Essers et al., 2005).

4.4 Wnt, GSK-3β, and NF-κB

Both Wnt1 and Akt1 also share a common pathway through the phosphorylation of GSK-3β (Chong & Maiese, 2007b). DVL is phosphorylated by casein kinase Iε to form a complex with Frat1 and inhibit GSK-3β activity. Cell injury during GSK-3β activation may occur through the phosphorylation of β-catenin that can lead to its ubiquitination and subsequent degradation. As a result, Wnt “anti-apoptotic” pathways can be dismantled in the absence of β-catenin and cannot support cell survival or block apoptosis (Chen et al., 2001; Li et al., 2006c; Terry et al., 2006; You et al., 2004). Modulation of GSK-3β activity can regulate progenitor cell proliferation and differentiation (Adachi et al., 2007; Wexler et al., 2007), promote midbrain differentiation (Castelo-Branco et al., 2004), control cardiac hypertrophy (Haq et al., 2000; Hardt & Sadoshima, 2002), and increase cell survival during oxidative stress, such as during neurofibrillary pathology (Wagner et al., 1997), amyloid toxicity (Chong et al., 2007a; Salins et al., 2007), and cardiac injury (van de Schans et al., 2007). GSK-3β activity also can influence inflammatory cell survival and activation (Chong et al., 2007a; Chong et al., 2007c; Li et al., 2006b). As a result, GSK-3β is considered to be an important treatment strategy for several degenerative disorders (Chong et al., 2005d, 2007b; Rowe et al., 2007; Wu et al., 2007b). For example, inactivation of GSK-3β by small molecule inhibitors or RNA interference prevents toxicity from high concentrations of glucose and increases rat beta cell replication, suggesting a possible target of GSK-3β for pancreatic beta cell regeneration in DM (Mussmann et al., 2007). Clinical applications for GSK-3β are especially attractive when considered in concert with trophic factors such as EPO. For example, both the potential benefits of EPO to improve cardiovascular function in diabetic patients (Silverberg et al., 2006; Silverberg et al., 2001)
and the positive effects of exercise to improve glycemic control during DM (Maiorana et al., 2002) appear to rely upon the inhibition of GSK-3β activity. EPO blocks GSK-3β activity (Chong et al., 2005d, 2007b; Rowe et al., 2007; Wu et al., 2007b) and combined with exercise may offer synergistic benefits, since physical exercise also has been shown to phosphorylate and inhibit GSK-3β activity (Howlett et al., 2006).

Protection through Wnt signaling also may require the activation of nuclear factor-κB (NF-κB). NF-κB proteins are composed of several homo- and heterodimer proteins that can bind to common DNA elements. It is the phosphorylation of IκB proteins by the IκB kinase (IKK) and their subsequent degradation that lead to the release of NF-κB for its translocation to the nucleus to initiate gene transcription (Hayden & Ghosh, 2004). Dependent upon Akt controlled pathways, the transactivation domain of the p65 subunit of NF-κB is activated by IKK and the IKKα catalytic subunit to lead to the induction of protective anti-apoptotic pathways (Chong et al., 2005b). NF-κB itself can be cytoprotective and lead to the induction of several anti-apoptotic genes, such as inhibitors of apoptotic proteins (IAPs), that can specifically inhibit caspases 3, 7, and 9 (Chong et al., 2005c; Li et al., 2006b; Spandou et al., 2006). Increased expression of NF-κB during injury models can occur in inflammatory microglial cells (Chong et al., 2005c, 2007b; Guo & Bhat, 2006) and in neurons (Sanz et al., 2002). NF-κB represents a critical pathway that is responsible for the maintenance of Bel-xL expression (Chen et al., 2000; Chong et al., 2005e) and the protection of cells against oxidative stress (Chong et al., 2005c). Although NF-κB has not consistently been found to be beneficial in all cell systems (Esposito et al., 2006b; Jacobsen et al., 2006) and sometimes may not be cytoprotective (Nurmi et al., 2006; Xu et al., 2005), cytoprotection through Wnt signaling in some scenarios has been associated with expression of NF-κB. In neuronal cell lines, over-expression of Wnt1 protects cells from serum deprivation and is accompanied by NF-κB activation (Bournat et al., 2000). In addition, sFRP2 appears to yield an anti-apoptotic effect in mammary cancer cells through NF-kappaB activation that may in addition require JNK suppression (Lee et al., 2006b).

5. Perspectives and Considerations for Wnt Signaling

As our appreciation for the expansive pathways governed by the Wnt pathway continue to unfold, both basic research as well as future clinical studies should provide direction for the potential therapeutic applications of Wnt. The scope of the Wnt pathway is exceedingly broad and is involved in the development of the brain, spinal cord, and the extension of numerous sub-populations of sensory and motor neurons. Furthermore, Wnt signaling regulates the processes of vascular remodeling, cardiac development, and cardiac hypertrophy. Integration of the nervous and cardiovascular systems through Wnt occurs at several cellular levels that relate to oxidative stress, apoptotic injury, and inflammatory cell activation eliciting excitement for the development of treatment strategies that range from the repair of infarcted cardiac tissue to the restoration of cognitive loss (Figure 3).

Unfortunately as with all therapeutic modalities, a “double edge sword” exists in regards to the benefits and risks of any treatment strategy. Although Wnt signaling is a critical component for the regulation of cell and tissue growth in the neuronal and vascular systems, Wnt can either facilitate or prevent apoptosis depending upon the environmental stimuli. This knowledge in regards to Wnt is of particular concern, since recent studies have shown that Wnt signaling can suppress apoptotic pathways during neoplastic growth and limit the effectiveness of treatments directed to control or eliminate tumor growth. In addition, in other studies that involve DM, neuronal disorders, or cardiac disease, it is not entirely evident whether mutations in genes of the Wnt pathway or alterations in protein expression of the Wnt pathway components during these disorders confer protective or detrimental effects. Therefore, it becomes imperative if the “protectionist” Wnt pathway is to offer us the ability to live well and “age gracefully” to clearly focus upon the multiple cellular mechanisms controlled by Wnt. Only with this conviction in
the forefront of objectives can we hope to offer patients robust and safe treatment regimens for a variety of disorders that can involve neurodegeneration, cardiac insufficiency and diabetes.

Acknowledgements

This research was supported by the following grants (KM): American Diabetes Association, American Heart Association (National), Bugher Foundation Award, Janssen Neuroscience Award, LEARN Foundation Award, MI Life Sciences Challenge Award, Nelson Foundation Award, NIH NIEHS (P30 ES06639), and NIH NINDS/NIA.

Abbreviations

Aβ  β-amyloid
APC  adenomatous polyposis coli
Akt  protein kinase B
Apaf-1  apoptotic protease-activating factor
BMP  bone morphogenetic protein
CaCN  calcineurin
Ca²⁺  calcium
CamKII  Ca²⁺-calmodulin-dependent protein kinase II
CARD  caspase recruitment domain
cGMP  cyclic guanosine monophosphate
DED  death effector domain
DM  diabetes mellitus
DVL  Dishevelled
EC  endothelial cell
EPO  erythropoietin
EPOR  erythropoietin receptor
FOX  Forkhead box
FZD  Frizzled
GSK-β  glycogen synthase kinase-β
IAP  inhibitor of apoptosis protein
IKK  IκB kinase
JNK  Jun N-terminal kinase
LRP  low-density lipoprotein receptor-related protein
ΔΨm  mitochondrial membrane potential
NF-κB  nuclear factor-κB
NO  nitric oxide
PI 3-K  phosphatidylinositol 3-kinase
PKC  protein kinase C
PS  phosphatidylserine
PSR  phosphatidylserine receptor
SOD  superoxide dismutase
Wg  Drosophila Wingless

References


Blankesteijn WM, Gijn MEv, Daemen MJAP, Wynshaw-Boris Smits JFM, Pratt RE. Alterations in the cadherin–catenin complex of dishevelled-1 knockout mice lead to infarct rupture after myocardial infarction. Circulation 1999;100(suppl):156.


Brigstock DR. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 2002;5(3):153–165. [PubMed: 12831056]


Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol 2007a;150(7):839–850. [PubMed: 17339844]


Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid...


Pharmacol Ther. Author manuscript; available in PMC 2009 April 1.


Ling PR, Mueller C, Smith RJ, Bistrian BR. Hyperglycemia induced by glucose infusion causes hepatic oxidative stress and systemic inflammation, but not STAT3 or MAP kinase activation in liver in rats. Metabolism 2003;52(7):868–874. [PubMed: 12870163]


Mirotou M, Zhang Z, Deb A, Zhang L, Guecchi M, Noisieux N, Mu H, Pachori A, Dzau V. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A 2007;104(5):1643–1648. [PubMed: 17251350]


Wexler EM, Geschwind DH, Palmer TD. Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry. 2007

Wiedau-Pazos M, Wong E, Solomon E, Alarcon M, Geschwind DH. Wnt-pathway activation during the early stage of neurodegeneration in FTDP-17 mice. Neurobiol Aging. 2007


Figure 1. Intracellular signaling for Wnt is mediated through the canonical and non-canonical pathways

A representative schematic for the canonical and non-canonical pathways is shown. The canonical Wnt signaling pathway is referred to as the Wnt/β-catenin pathway since it can regulate β-catenin. All Wnt signaling pathways are initiated by interaction of Wnt proteins with Frizzled (FZD) receptors. The Wnt signaling pathway will only be activated if the binding of the Wnt protein to the FZD receptor takes place in the presence of the co-receptor LRP-5/6 resulting in the formation of a Wnt-FZD-LRP-5/6 tri-molecular complex. Once Wnt protein binds to the FZD receptor and the co-receptor LRP-5/6, this is followed by recruitment of Dishevelled (DVL). DVL is phosphorylated by casein kinase Iε to form a complex with Frat1 and inhibit glycogen synthase kinase (GSK-3β) activity. The non-canonical or atypical Wnt signaling pathway has two intracellular signaling cascades that consist of the Wnt/Ca²⁺ pathway and the Wnt/PCP pathway. In the Wnt/Ca²⁺ pathway, Wnt protein binds to FZD receptors on the cell surface resulting in several cellular processes that involve stimulation of heterotrimeric G proteins, increased intracellular Ca²⁺ release, decreased cyclic guanosine monophosphate (cGMP) levels, and activation of the two kinases Ca²⁺-calmodulin-dependent protein kinase II (CamKII) or calcineurin (CaCN) and protein kinase C (PKC). Activation of these pathways can stimulate several transcription factors. In the Wnt/PCP pathway, Wnt proteins bind to FZD receptors on the cell surface followed by activating Rho/Rac small GTPase and Jun N-terminal kinase (JNK) to assist with cytoskeletal organization and gene expression.
Figure 2. Wnt1 promotes nuclear translocation of β-catenin during amyloid-beta (Aβ) exposure. Immunofluorescence staining for β-catenin was performed at 12 hours following Aβ_{1-42} (20 μM) application in SH-SY5Y cells by using rabbit anti-β-catenin antibody followed by Texas-red labeled anti-rabbit second antibody. The nucleus was counterstained with DAPI. Representative pictures of staining for β-catenin, DAPI, and merged images are illustrated. In control untreated cells, β-catenin is expressed in both nucleus and cytoplasm. Aβ_{1-42} application resulted in predominant distribution of β-catenin in the cytoplasm. However, the expression of β-catenin was mainly observed in nucleus in Wnt1 over-expressing SH-SY5Y cells. In merged images, cells with Aβ_{1-42} exposure show decreased β-catenin staining (blue) in the nucleus while Wnt1 over-expression reveals strong β-catenin staining in the nucleus (red).
Figure 3. Wnt signaling is cytoprotective through the modulation of multiple cellular pathways

Wnt signaling begins with Frizzled (FZD) receptors resulting in the activation of Dishevelled (DVL) followed by the inhibition of glycogen synthase kinase (GSK-3β), Axin, and adenomatous polyposis coli (APC) tumor suppressor protein complex. The suppressed GSK-3β, Axin and APC complex prevents phosphorylation (p) of β-catenin and leads to the accumulation of β-catenin. β-catenin enters into cellular nucleus and contributes to the formation of Lef/Tcf lymphocyte enhancer factor/T cell factor (Lef/Tcf) and β-catenin complex that may cooperate with factors activated by other signaling pathways resulting in cellular proliferation, differentiation, survival and apoptosis through the induction of target nuclear gene transcription. Interconnected pathways with Wnt involve IκB kinase (IKK), IκB, inhibitors of apoptotic protein (IAPs), the forkhead family members (FOXO), glycogen synthase kinase-3β (GSK-3β), nuclear factor-κB (NF-κB), mitochondrial membrane potential (ΔΨm), cytochrome c, (Cyto-c), and caspases. Ultimately these pathways converge upon early apoptotic injury with phosphatidylserine (PS) exposure and later apoptotic DNA degradation.
### Table 1
Cellular Expression of the Wnt and the Wnt-FZD Receptor with Biological Response

<table>
<thead>
<tr>
<th>Cellular Expression of Wnt</th>
<th>Cellular Expression of Wnt-FZD Receptor</th>
<th>Biological Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurons</td>
<td>Neurons</td>
<td>Brain development and resistance to injury</td>
</tr>
<tr>
<td>Astrocytes</td>
<td>Astrocytes</td>
<td>Brain development and protection</td>
</tr>
<tr>
<td>Progenitor stem cells</td>
<td>Progenitor stem cells</td>
<td>Cellular development and maturation</td>
</tr>
<tr>
<td>Endothelial cells</td>
<td>Endothelial cells</td>
<td>Angiogenesis</td>
</tr>
<tr>
<td>Progenitor vascular stem cells</td>
<td>Progenitor vascular stem cells</td>
<td>Angiogenesis and cardiomyogenesis</td>
</tr>
<tr>
<td>Vascular smooth muscle cells</td>
<td>Vascular smooth muscle cells</td>
<td>Angiogenesis, vascular remodeling, and cytoprotection</td>
</tr>
<tr>
<td>Progenitor cardiac stem cells</td>
<td>Progenitor cardiac stem cells</td>
<td>Cardiomyogenesis</td>
</tr>
<tr>
<td>Endocardial cells</td>
<td>Endocardial cells</td>
<td>Endocardial cushion formation</td>
</tr>
<tr>
<td>Cardiomyocytes</td>
<td>Cardiomyocytes</td>
<td>Cardiac remodeling and cytoprotection</td>
</tr>
</tbody>
</table>

*Pharmacol Ther. Author manuscript; available in PMC 2009 April 1.*
# Table 2
Wnt Signaling Pathway in the Diseases of the Nervous and Cardiovascular Systems

<table>
<thead>
<tr>
<th>Clinical or Biological Presentation</th>
<th>Wnt Signaling Components</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s disease</td>
<td>Wnt signaling down-regulated by presenilin 1&lt;br&gt;β-amyloid production increased&lt;br&gt;LRP-6 variants, possible neurofibrillary changes</td>
<td>β-catenin degradation increased&lt;br&gt;GSK-3β activity increased and β-catenin activity decreased; apoptotic neuronal injury increased; microglial activation increased</td>
</tr>
<tr>
<td>Retinitis pigmentosa</td>
<td>Wnt inhibitory protein Fzd-related protein-2 secretion increased</td>
<td>Increased loss of photoreceptors</td>
</tr>
<tr>
<td>Angiogenesis and inflammatory cell control</td>
<td>Wnt1 expression increased&lt;br&gt;Wnt1 and β-catenin expression increased&lt;br&gt;Frz A expression increased&lt;br&gt;Fzd 4 increased; CAMKII and PKC activated&lt;br&gt;DVL expression and β-catenin increased&lt;br&gt;Wnt1 activation</td>
<td>HUVEC proliferation inhibited; HUVEC morphology altered&lt;br&gt;EC and VSMC proliferation increased&lt;br&gt;Vessel density increased&lt;br&gt;Retinal angiogenesis increased&lt;br&gt;Neovascularization increased&lt;br&gt;Reduction in inflammatory cell activation&lt;br&gt;VSMC survival increased and apoptosis decreased&lt;br&gt;Proliferating vascular ECs decreased&lt;br&gt;Infarct size, leukocyte infiltration, and apoptosis decreased&lt;br&gt;Cardiac apoptosis decreased; cardiomyocyte adherence enhanced; cardiac function improved&lt;br&gt;Decreased pressure induced cardiac hypertrophy&lt;br&gt;Decreased pressure induced cardiac hypertrophy</td>
</tr>
<tr>
<td>Arterial injury</td>
<td>β-catenin accumulation increased</td>
<td>Vascular/renal cell early and late apoptosis&lt;br&gt;Glucose intolerance</td>
</tr>
<tr>
<td>Cardiac injury/Pressure overload</td>
<td>β-catenin expression increased DVL-1 decreased&lt;br&gt;Increased FZD gene expression</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Wnt signaling increased with hyperglycemia; trophic factor enhanced Wnt1 expression&lt;br&gt;Missense mutations LRP-6</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CAMKII, calcium/calmodulin-dependent protein kinase II; EC, DVL, disheveled; endothelial cell; Fzd, Frizzled; GSK-3β, glycogen synthase kinase-3β; HUVEC, human umbilical vein endothelial cell; LRP, low-density lipoprotein receptor-related protein; VSMC, vascular smooth muscle cell.